Improving the efficacy of engineered T-cells – from gene transfer to genome editing
A new level of sophistication, namely genome editing, is now available to help overcome previous hurdles with adoptive T-cell therapies
Cancer Control Principles
You are not your COI, but COI can make you
There is a misunderstanding in what financial conflict of interests do on single people and what system implications they may have
Cancer Research
Artificial Intelligence: a ‘smart’ arrow in our quiver against cancer
Many studies presented at ESMO Congress 2022 show the potential of artificial intelligence to enhance personalised oncology
Prostate cancer: data support adding ADT for patients undergoing post-operative radiotherapy
Results from the RADICALS-HD and PRESTO trials show encouraging metastasis-free and biochemical progression-free survival benefits with androgen deprivation therapy, but they are not practice-changing yet
Sotorasib improves PFS versus docetaxel in patients with pre-treated KRAS G12C-mutated NSCLC
Results from the CodeBreaK 200 trial represent an improvement for a difficult-to-treat patient population
Could anti-PD-L1 be the best choice as front-line therapy in platinum-ineligible patients with NSCLC?
Findings show overall survival benefits with front-line atezolizumab versus single-agent chemotherapy, but questions remain regarding who might benefit
First-line triplet of TKI plus dual immunotherapy improves outcomes in renal cell carcinoma
Results from the COSMIC-313 trial show that adding cabozantinib to nivolumab plus ipilimumab prolongs progression-free survival, but also increases toxicity
Antibody–drug conjugates show potential in advanced solid tumours
Study data report promising responses and safety profiles in patients with heavily pre-treated malignancies
NECs: mixed results for second-line therapy after progression
The optimal chemotherapy regimen in this setting is not well-defined
The first randomised study of peptide receptor radionuclide therapy in pancreatic NETs met its primary endpoint
In the OCLURANDOM trial, progression-free survival was longer in patients receiving lutetium-octreotate versus sunitinib